comparemela.com

Latest Breaking News On - Michael pehl - Page 1 : comparemela.com

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors.Funds will be used to further strengthen growing pipeline of first in

Iyona rajkomarMichael pehlHealthcare strategic growth fundNovo holdingsDawn biopharmaManaging partnerAdcendo boardYsios capitalGilde healthcarePontifax ventureDevelopment candidate nominationChief executive officerBoard directorPontifax venture capitalStrategic growth fundIhr portfolio

Adcendo Raises €16M; Extends Series A to €98M

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Michael pehlIyona rajkomarNovo holdingsDawn biopharmaYsios capitalGilde healthcarePontifax ventureManaging partnerAdcendo board

Adcendo Appoints Experienced Drug Developer Dr Lone H Ottesen as Chief Medical Officer

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of.

Michael pehlStage clinical developmentDevelopment officerNovo holdingsAarhus universityGlobal oncology developmentAdcendo apsChief medical officerGlobal clinical headLate stage clinicalChief developmentChief executive officerDuality biologicsYsios capitalPontifax venture capital

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of.

John zhuMichael pehlNovo holdingsDuality biologicsDuality immune toxin antibody conjugatesOption license agreementChief executive officerYsios capitalPontifax venture capital

Adcendo expands partnership with Duality Biologics

Adcendo has expanded its partnership with fellow biotech company Duality Biologics, in an effort to "broaden and expand" the collaboration.

Michael pehlJohn zhuDuality immune toxin antibody conjugatesOption license agreementDuality biologicsBio developmentsMarkets amp regulationsEmerging markets

vimarsana © 2020. All Rights Reserved.